ImClone Suffers Erbitux Setback, Says It Won t Need New Trials
By Kim Coghill
Thursday, January 3, 2002
Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.